https://pharminent.com/fda-approves-priovants-lisraya-brepocitinib-the-first-targeted-therapy-for-dermatomyositis/ 2026-08-28T00:35:39Z Pharminent en FDA Approves Priovant's LISRAYA (Brepocitinib), the First Targeted Therapy for Dermatomyositis 2026-08-28T00:35:36Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-27-2026/ 2026-08-28T00:16:08Z Pharminent en Strategic News Watch • August 27, 2026 2026-08-28T00:16:06Z Blog https://pharminent.com/fda-approves-revolution-medicines-rasonque-first-rason-inhibitor-for-metastatic-pancreatic-cancer/ 2026-08-26T20:48:11Z Pharminent en FDA Approves Revolution Medicines' Rasonque, First RAS(ON) Inhibitor for Metastatic Pancreatic Cancer 2026-08-26T20:07:12Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-26-2026/ 2026-08-26T19:29:24Z Pharminent en Strategic News Watch • August 26, 2026 2026-08-26T19:29:21Z Blog https://pharminent.com/__trashed-4/ 2026-08-26T17:05:58Z Pharminent en Spyre deprioritises arthritis drug after Phase 2 results 2026-08-26T14:52:12Z Blog https://pharminent.com/__trashed-16/ 2026-08-26T17:05:00Z Pharminent en Jazz secures FDA approval for Ziihera in advanced HER2+ GEA 2026-08-26T10:08:44Z Blog